Entresto® (sacubitril/valsartan) – New indication
October 2, 2019 - Novartis announced the FDA approval of Entresto (sacubitril/valsartan), for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Entresto reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) and is expected to improve cardiovascular (CV) outcomes.
Top